Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Johnson & Johnson
JNJ · NYSE · Pharmaceuticals
$272.70−6.00 (−2.15%)
Close of Nov 18, 2026, vs Nov 17 · end-of-day, not a live quote
Johnson & Johnson (JNJ) · oqro.io/stocks/JNJ · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
0 open-market purchases and 29 open-market sales by insiders of JNJ between Dec 22, 2025 and today, placed against the company's last 4 earnings releases. The latest on file was filed Oct 13, 2026. The data provider lists the next release for Jan 26, 2027; that date may change.
PurchaseSale30 days before a release30 days after
Trades in the 30 days around each of the last earnings releases
Elizabeth Forminard, EVP, Chief Legal Officer, Nov 12, 2026, about $3.72M. Sold 30 days after the company's previous earnings release on 2026-10-13Form 4
Timothy Schmid, EVP, WW Chair, MedTech, Sep 2, 2026, about $3.04M. Sold 41 days before the company's next earnings release on 2026-10-13Form 4
Timothy Schmid, EVP, WW Chair, MedTech, Sep 2, 2026, about $6.19M. Sold 41 days before the company's next earnings release on 2026-10-13Form 4
Jennifer L Taubert, EVP, WWC. Innovative Medicine, Aug 17, 2026, about $3.95M. Sold 33 days after the company's previous earnings release on 2026-07-15Form 4
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies
Joaquin Duato, CEO and Chairman of the Board, Aug 13, 2026, about $5.5M. Sold 29 days after the company's previous earnings release on 2026-07-15
Joaquin Duato, CEO and Chairman of the Board, Aug 13, 2026, about $26.7M. Sold 29 days after the company's previous earnings release on 2026-07-15Form 4
Elizabeth Forminard, EVP, Chief Legal Officer, Aug 6, 2026, about $2.41M. Sold 22 days after the company's previous earnings release on 2026-07-15Form 4
Elizabeth Forminard, EVP, Chief Legal Officer, Aug 6, 2026, about $1.68M. Sold 22 days after the company's previous earnings release on 2026-07-15Form 4
Joaquin Duato, CEO and Chairman of the Board, Aug 5, 2026, about $10.8M. Sold 21 days after the company's previous earnings release on 2026-07-15Form 4
Joaquin Duato, CEO and Chairman of the Board, Aug 5, 2026, about $1.69M. Sold 21 days after the company's previous earnings release on 2026-07-15Form 4